echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Blood System > "Nature": ctDNA testing helps personalized diagnosis and treatment of bladder cancer

    "Nature": ctDNA testing helps personalized diagnosis and treatment of bladder cancer

    • Last Update: 2021-07-31
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Globally, there will be approximately 573,000 bladder cancer patients and 212,000 deaths in 2020


    In order to identify patients with increased likelihood of residual disease after surgery, a blood test is used to detect the presence of circulating tumor genes (ctDNA)


    CtDNA from solid tumors is released into the blood

    CtDNA from solid tumors is released into the blood

    According to a clinical study conducted by Queen Mary University of London, blood tests related to ctDNA may be able to identify the risk of cancer recurrence and guide the precise treatment of bladder cancer after surgery.


    Detection of ctDNA shortly after surgery may overcome clinical limitations.


    Thomas Powles et al, ctDNA guiding adjuvant immunotherapy in urothelial carcinoma, Nature (2021).


    Thomas Powles et al, ctDNA guiding adjuvant immunotherapy in urothelial carcinoma, Nature (2021).


    The researchers evaluated the treatment results of patients (581 people) in the randomized phase III trial (IMvigor010) and phase II study (ABACUS), and analyzed whether the drug Atezolizumab can reduce the recurrence of high-risk invasive urothelial cancer


    The research team found that patients who were positive for ctDNA in their blood after surgery had a higher risk of cancer recurrence than those who were negative for ctDNA


    Patients who are positive for ctDNA in their blood after surgery have a higher risk of cancer recurrence than those who are negative for ctDNA


    Patients with ctDNA positive have improved disease-free survival and overall survival in the atezolizumab treatment group


    The adjuvant use of atezolizumab may be related to improving the prognosis of patients


    ctDNA testing is more accurate than traditional radiology in identifying disease recurrence


    Original source:

    https:// href="https://" target="_blank" rel="noopener">https://


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.